Search
Hypertension Paid Clinical Trials in Kansas
A listing of 20 Hypertension clinical trials in Kansas actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 20
The state of Kansas currently has 20 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Wichita, Kansas City, Overland Park and Topeka.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Obese or Overweight Volunteers Needed for a Research Study
Recruiting
Enroll now in a research study for obese or overweight volunteers with heart disease, hypertension, T2DM, or high cholesterol. All study related assessments are provided at no cost. Compensation up to $125 per visit for qualified participants.
Conditions:
Obesity
Overweight
Overweight and Obesity
Diabetes Mellitus
Type 2
Featured Trial
Heart Failure Clinical Trial
Recruiting
You or someone you love may be eligible for a heart failure clinical study. Eligible participants will receive study-related assessments, care, and treatment at no cost. You may be reimbursed for travel while participating. See if you are eligible.
Conditions:
Heart Failure
Congestive Heart Failure
Chronic Heart Failure
Heart Failure
Congestive
Pulmonary Hypertension Biorepository and Registry
Recruiting
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Pulmonary Hypertension Association Registry
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S.
PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: KU Medical Center, Kansas City, Kansas
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Recruiting
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.
Participants are put into 2 gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: AMR El Dorado, El Dorado, Kansas +2 locations
Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/24/2025
Locations: University of Kansas Medical Center-IM-Pulmonary and Critical Care Medicine ( Site 0102), Kansas City, Kansas
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas +1 locations
Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Recruiting
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Kansas University Medical Center, Kansas City, Kansas
Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Recruiting
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/17/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Arterial Hypertension
Global Paradise System US Post Approval Study
Recruiting
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Ascension via Christi St. Francis, Wichita, Kansas
Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Recruiting
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN.
This study consists of a screening, a 4-week dapagliflozin run-in period for participants naïve to SGLT2i at baseline; a 24-month double-blind period in which participants will receive either baxdrostat/dapagliflozin or dapagliflozin; and a 6-week open-label period in which all participants will discontinue baxdrostat/placebo and receive dapagliflozin a... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/11/2025
Locations: Research Site, Hutchinson, Kansas +1 locations
Conditions: Chronic Kidney Disease and Hypertension
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/09/2025
Locations: Alliance for Multispecialty Resrch, Wichita, Kansas
Conditions: Hypertension
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Recruiting
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Hutchinson, Kansas +2 locations
Conditions: Chronic Kidney Disease and Hypertension
1 - 12 of 20